The immune spectrum in patients with lung cancer.

概要

論文の詳細を見る
The relationship between the immune responses and clinical manifestations in 58 patients with lung cancer was examined with a coordinated program of natural killer (NK) cell activity and delayed-type hypersensitivity reaction to dinitrochlorobenzene (DNCB).<BR>Patients were divided into four groups:(A) normal NK cell activity (≥25%) and positive reaction to DNCB, (B) normal NK cell activity but negative reaction to DNCB, (C) subnormal NK cell activity (<25%) but positive reaction to DNCB, (D) subnormal NK cell activity and negative reaction to DNCB.<BR>Group A patients were characterized by good performance status, low tumor burden and high response rate (82%) to therapy, but group D patients were characterized by poor performance status, high tumor burden and no response to therapy. Group B and C patients showed intermediate patterns.<BR>The immune spectrum presented here was shown to be related to the clinical manifestations. The simple method of immune spectrum evaluation might be a useful tool in the management of lung cancer patients.
特定非営利活動法人日本肺癌学会の論文